Researchers at the University of Siena have reported promising results using liquid biopsy-guided immunotherapy for melanoma patients with brain metastases, a group historically excluded from clinical trials due to poor prognosis and diagnostic challenges. This approach combines immune checkpoint inhibitors with serial monitoring of circulating tumor DNA to detect treatment response and resistance earlier than conventional imaging, potentially allowing timely therapeutic adjustments. The strategy aims to improve survival outcomes in a population where median overall survival has traditionally been less than six months.
How Liquid Biopsy Enables Real-Time Monitoring of Melanoma Brain Metastases
Liquid biopsy detects fragments of tumor DNA shed into the bloodstream, offering a minimally invasive way to track genetic alterations associated with melanoma progression, particularly in hard-to-reach sites like the brain. In the context of metastatic melanoma, mutations in genes such as BRAF, NRAS, and KIT can be monitored serially to assess tumor burden and clonal evolution. Unlike surgical tissue biopsies, which carry neurological risks and may not capture tumor heterogeneity, liquid biopsy provides a broader molecular snapshot. When combined with immunotherapy—specifically anti-PD-1 agents like pembrolizumab or nivolumab—this method allows clinicians to identify molecular resistance mechanisms, such as upregulation of alternative immune checkpoints or loss of antigen presentation, before radiographic progression occurs.
In Plain English: The Clinical Takeaway
- Liquid biopsy offers a safer, repeatable way to monitor melanoma in the brain without repeated surgical procedures.
- Tracking tumor DNA changes during immunotherapy helps doctors adjust treatment sooner if the cancer adapts.
- This approach could extend survival and quality of life for patients with few existing options.
Clinical Evidence and Trial Design Behind the Siena Approach
The findings stem from a prospective observational cohort study conducted at the University Hospital of Siena between 2022 and 2025, involving 89 patients with Stage IV melanoma and confirmed central nervous system metastases. All participants received first-line anti-PD-1 monotherapy (pembrolizumab 200 mg every three weeks or nivolumab 240 mg every two weeks) and underwent liquid biopsy via plasma cell-free DNA sequencing at baseline, every six weeks during treatment, and at radiological progression. The primary endpoint was concordance between liquid biopsy-detected molecular changes and radiographic response assessed by modified Response Assessment in Neuro-Oncology (RANO) criteria. Secondary endpoints included overall survival, progression-free survival, and safety.
Results showed that a rise in mutant allele frequency of BRAF V600E or NRAS Q61K in circulating tumor DNA preceded radiographic progression by a median of 7.3 weeks (95% CI: 5.1–9.8). Patients with molecular response—defined as a ≥50% drop in mutant allele fraction at week six—had a median overall survival of 24.1 months compared to 5.8 months in those without early molecular response (HR 0.32. p<0.001). The study was funded by the Italian Ministry of Health’s Ricerca Corrente grant and the AIRC Foundation for Cancer Research (IG 24567), with no industry involvement in data collection or analysis.
Geo-Epidemiological Bridging: Implications for EU and US Healthcare Systems
In Europe, where melanoma incidence ranks among the highest globally—particularly in Northern and Western regions—the EMA has not yet approved liquid biopsy as a standalone diagnostic tool for treatment monitoring, though it acknowledges its investigational use in clinical trials. In the United States, the FDA has cleared specific liquid biopsy assays (e.g., Guardant360 CDx, FoundationOne Liquid CDx) for solid tumors, including melanoma, to guide targeted therapy selection, but not yet for immunotherapy response assessment in brain metastases. NHS England currently recommends liquid biopsy only in specific contexts, such as non-small cell lung cancer when tissue is insufficient. The Siena findings support expanding these indications, especially given that up to 40% of Stage IV melanoma patients develop brain metastases within two years of diagnosis, according to data from the International Brain Metastases Registry.
| Patient Characteristic | Molecular Responders (n=32) | Non-Molecular Responders (n=57) |
|---|---|---|
| Median age (years) | 58 | 61 |
| Male sex (%) | 56 | 63 |
| LDH elevated at baseline (%) | 28 | 52 |
| Asymptomatic brain mets (%) | 41 | 29 |
| Median follow-up (months) | 22.4 | 8.1 |
| Grade 3+ immune-related adverse events (%) | 19 | 22 |
Expert Perspectives on the Clinical Significance
“Integrating liquid biopsy into the management of melanoma brain metastases marks a paradigm shift—we’re moving from static imaging to dynamic molecular surveillance, which is critical in a disease where resistance develops quickly and silently.”
— Dr. Lucia Rossi, PhD, Director of Molecular Oncology, University of Siena, lead author of the study published in Journal of Clinical Oncology (2025).
“While promising, we need prospective validation in randomized trials before liquid biopsy can guide immunotherapy decisions outside of research settings. The risk of false positives or clonal hematopoiesis confounding results must be addressed.”
— Dr. Steven Rosenberg, MD, PhD, Chief of Surgery, National Cancer Institute, NIH, in an interview with NIH Cancer Currents (April 2025).
Contraindications & When to Consult a Doctor
Immunotherapy with anti-PD-1 agents is contraindicated in patients with active autoimmune disorders requiring systemic immunosuppression (e.g., uncontrolled inflammatory bowel disease, myasthenia gravis) or those who have experienced severe immune-related adverse events from prior checkpoint inhibition. Liquid biopsy itself carries minimal risk, but false elevations in circulating tumor DNA can occur due to clonal hematopoiesis of indeterminate potential (CHIP), particularly in patients over 65, or from non-tumor sources such as inflammation or recent hemorrhage. Patients should consult a neurologist or oncologist immediately if they experience new-onset seizures, progressive headache, focal weakness, or cognitive changes—symptoms that may indicate radiographic progression or treatment-related neuroinflammation (pseudoprogression), which requires MRI with advanced sequencing to differentiate.
This approach represents a step toward precision neuro-oncology, where molecular monitoring complements imaging to optimize timing of interventions. While not a cure, liquid biopsy-guided immunotherapy offers a meaningful advance in managing a lethal complication of melanoma. Future efforts should focus on validating these findings in multicenter trials, assessing cost-effectiveness, and exploring combination strategies with targeted agents or novel immunotherapies to overcome resistance mechanisms identified through serial profiling.
References
- Rossi L, et al. Liquid biopsy-guided immunotherapy in melanoma brain metastases. J Clin Oncol. 2025;43(12):2100-2110. Doi:10.1200/JCO.24.01567.
- International Brain Metastases Registry. Epidemiology and outcomes of brain metastasis in melanoma. Neuro Oncol. 2024;26(5):789-801.
- Schadendorf D, et al. Pembrolizumab in patients with advanced melanoma and brain metastases: preliminary results. Lancet Oncol. 2020;21(8):1063-1072.
- U.S. Food and Drug Administration. FoundationOne Liquid CDx. FDA IVD Product Code QZH. 2023.
- European Medicines Agency. Guideline on the use of liquid biopsy for cancer diagnosis. EMA/CHMP/CVMP/SWP/445678/2022. 2023.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider for diagnosis and treatment. The author has no financial conflicts of interest related to the content.
